Macitentan and Tadalafil Combination Therapy in Patients with Pulmonary Arterial Hypertension and Cardiovascular Comorbidities: Real-World Evidence from OPUS and OrPHeUS

By sjmartinez • May 20, 2025

Kim NH, Chin KM, McLaughlin VV, Ong R, MacDonald G, Martin N, Senatore A, Channick R. Macitentan and Tadalafil Combination Therapy in Patients with Pulmonary Arterial Hypertension and Cardiovascular Comorbidities: Real-World Evidence from OPUS and OrPHeUS. Adv Ther. 2025 May 19. doi: 10.1007/s12325-025-03180-0. Epub ahead of print. PMID: 40388087.

Tags: Cardiovascular comorbidities, combination therapy, Hospitalization, Macitentan, Publications, pulmonary arterial hypertension, Pulmonary, Critical Care & Sleep Medicine, real-world data, safety, survival, Tadalafil

The role of declining therapy volumes in skilled nursing facility outcomes: a mediation analysis

Prusynski RA, Humbert A, Amaravadi H, Burke RE, Saliba D, Leland NE, Freburger J, Mroz TM. The role of declining therapy volumes in skilled nursing[...]

Bloodstream Infections Among Veterans With Cardiac Implantable Electronic Devices: Source Identification and Intervention Strategies

Basnet D, Golenbock S, Strymish JM, Mull HJ, Lamkin RP, Shin M, Harvey K, Karchmer AW, Branch-Elliman W. Bloodstream Infections Among Veterans With Cardiac Implantable[...]

FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma

Corren J, Reid F, Moate R, Jimenez E, Sadiq MW, Williams A, Rytelewski M, Cameron-Christie S, Muthas D, Georgi B, Brooks D, Lindqvist E, Kell[...]